| abstract |
Disclosed are the preparation of a novel strain capable of producing an alpha-glucosidase inhibitor on the basis of a salbostatin biosynthetic gene cluster, and the mass-scale production of the alpha-glucosidase inhibitor. A 17-kb gene cluster, derived from the salbostatin-producing strain Streptomyces albus KCTC 9015, encoding 14 enzymes from sa1H to salU, is cloned into an expression vector which is then transformed into a Streptomyces strain in which the alpha-glucosidase inhibitors valienamine or valiolamine can be thus expressed in a large quantity. Thus, it allows diabetes drugs to be produced at low cost because valienamine or valiolamine are used as materials for their production. |